

October 13, 2017



## **BioSig Technologies to Present at the Dawson James Small Cap Growth Conference**

Minneapolis, MN, Oct. 13, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for the \$4.6 billion electrophysiology (EP) marketplace, today announced that management will be presenting at the 3rd Annual Dawson James Small Cap Growth Conference. The conference will be taking place on October 18-19 at Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida.

Kenneth Londoner, Chairman and CEO of BioSig Technologies, is scheduled to present at 10:00am on Thursday, October 19th. The presentation will cover the Company overview as well as recent highlights.

To attend the conference, please register directly via this link:

<http://dawsonjames.com/wp-content/uploads/2017/08/PLEASE-SAVE-THE-DATE-FOR-THE-DAWSON-JAMES2017August31.pdf>

To schedule a one-on-one meeting with BioSig, please contact Natasha Russkina, VP Business Development and Corporate Finance at [nrusskina@biosigtech.com](mailto:nrusskina@biosigtech.com).

### **About BioSig Technologies**

BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the \$4.6 billion electrophysiology (EP) marketplace ([www.biosigtech.com](http://www.biosigtech.com)). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market.

The PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig's main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.

### **Forward-looking Statements**

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at <http://www.sec.gov>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contact:

Natasha Russkina  
BioSig Technologies, Inc.  
VP Business Development & Corporate Finance  
[nrusskina@biosigtech.com](mailto:nrusskina@biosigtech.com)



Source: BioSig Technologies, Inc.